Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of

Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is resp

Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the se

The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patien

Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplant

As a result of market dominance by agents such as leuprolide, and AstraZeneca’s Zoladex (goserelin) and Casodex (bicalutamide), there is little space in the antihormonal therapies market for new competition unless significant clinical superiority

Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established cl

Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation.

Postoperative pain can be caused by many different surgical procedures, each involving a variety of complications and physician specialties. Pain is a subjective experience for patients and it would seem that prescribing is driven by physicians` subjec

COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands

Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued tr

Hypertension is a deadly disease and an important global public health challenge. Datamonitor estimates that there are currently 192m people with hypertension in the seven major markets, and this number is set to rise to 212m by 2015. Yet, a significan

HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the

According to the US National Heart, Lung, and Blood Institute and the European Respiratory Society, the annual cost of asthma is estimated to be $16.1 billion in the US and $16.3 billion in the EU. Over 41.5 million people, equivalent to the population

Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of ge

Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of cognitive impairment in schizophrenia (CIS). However manufacturers will need to carefully consider

Psoriasis is a non-life threatening but highly debilitating disease that currently has no cure. Traditional treatments often either lack efficacy or are effective but have very poor side-effect profiles, limiting them to use in severe disease only. How

During the past two decades, heart failure has emerged as a major chronic disease among the elderly population in the major pharmaceutical markets. The leading cause of hospitalization among patients over the age of 65 in Western markets, heart failure

The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of ph

Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer. In recent days, however, agents such as Sanofi-Aventis`s Taxotere and AstraZeneca`s Arimidex have been gaining prominence. This report examin

Stroke is one of the top three causes of death and incidence is expected to increase in the next ten years. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awaren

Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served patie

Fibromyalgia is a relatively common chronic pain syndrome, affecting around 2% of the population. This little understood market suffers from high unmet need both at the level of drug research and current clinical practice. Several leading industry pla

Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is made

With millions of diabetes patients suffering from neuropathic pain worldwide and no treatments yet approved for this indication in the US, the diabetic neuropathic pain (DNP) market is set for some dramatic changes. Key market events in the next few y

The bipolar disorder market is experiencing a renewed expansion in product life-cycle management. Presently, mood stabilizers are the basis of treatment, although the antipsychotics led by Zyprexa, are evolving as a new therapeutic strategy. Companies